Acute myeloid leukemia (AML) is a clonal heterogeneous disease of the myeloid white blood cells. It is characterised by an accumulation of immature blast cells and a number of chromosomal and genetic mutations have been identified. In both de novo and therapy-related AML, defective DNA repair mechanisms are responsible for some of these genetic abnormalities. Targeting the DNA repair mechanism has been shown to be successful against certain forms of solid tumors and may represent a novel therapeutic approach for AML.
KeywordsDNA RepairAcute Myeloid Leukemia
Link, D.C. (2012) Molecular Genetics of AML. Best Practice & Research Clinical Haematology, 25, 409-414. https://doi.org/10.1016/j.beha.2012.10.002
Shlush, L.I. and Mitchell, A. (2015) AML Evolution from Preleukemia to Leukemia and Relapse. Best Practice & Research Clinical Haematology, 28, 81-89. https://doi.org/10.1016/j.beha.2015.10.004
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., et al. (2016) Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England Journal of Medicine, 374, 2209-2221. https://doi.org/10.1056/NEJMoa1516192
Esposito, M.T. and So, C.W. (2014) DNA Damage Accumulation and Repair Defects in Acute Myeloid Leukemia: Implications for Pathogenesis, Disease Progression, and Chemotherapy Resistance. Chromosoma, 123, 545-561. https://doi.org/10.1007/s00412-014-0482-9
Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., et al. (2010) Refinement of Cytogenetic Classification in Acute Myeloid Leukemia: Determination of Prognostic Significance of Rare Recurring Chromosomal Abnormalities among 5876 Younger Adult Patients Treated in the United Kingdom Medical Research Council Trials. Blood, 116, 354-365. https://doi.org/10.1182/blood-2009-11-254441
Gavande, N.S., VanderVere-Carozza, P.S., Hinshaw, H.D., Jalal, S.I., Sears, C.R., Pawelczak, K.S., et al. (2016) DNA Repair Targeted Therapy: The Past or Future of Cancer Treatment? Pharmacology & Therapeutics, 160, 65-83.
Casorelli, I., Bossa, C. and Bignami, M. (2012) DNA Damage and Repair in Human Cancer: Molecular Mechanisms and Contribution to Therapy-Related Leukemias. International Journal of Environmental Research and Public Health, 9, 2636-2657. https://doi.org/10.3390/ijerph9082636
Hasserjian, R.P. (2013) Acute Myeloid Leukemia: Advances in Diagnosis and Classification. International Journal of Laboratory Hematology, 35, 358-366. https://doi.org/10.1111/ijlh.12081
Zhang, Y. and Rowley, J.D. (2006) Chromatin Structural Elements and Chromosomal Translocations in Leukemia. DNA Repair (Amst), 5, 1282-1297.
Churpek, J.E. and Larson, R.A. (2013) The Evolving Challenge of Therapy-Related Myeloid Neoplasms. Best Practice & Research Clinical Haematology, 26, 309-317. https://doi.org/10.1016/j.beha.2013.09.001
D’Andrea, A.D. (2010) Targeting DNA Repair Pathways in AML. Best Practice & Research Clinical Haematology, 23, 469-473.
Rollinson, S., Smith, A.G., Allan, J.M., Adamson, P.J., Scott, K., Skibola, C.F., et al. (2007) RAD51 Homologous Recombination Repair Gene Haplotypes and Risk of Acute Myeloid Leukaemia. Leukemia Research, 31, 169-174.
Esposito, M.T., Zhao, L., Fung, T.K., Rane, J.K., Wilson, A., Martin, N., et al. (2015) Synthetic Lethal Targeting of Oncogenic Transcription Factors in Acute Leukemia by PARP Inhibitors. Nature Medicine, 21, 1481-1490. https://doi.org/10.1038/nm.3993
Kelley, M.R., Logsdon, D. and Fishel, M.L. (2014) Targeting DNA Repair Pathways for Cancer Treatment: What’s New? Future Oncology, 10, 1215-1237. https://doi.org/10.2217/fon.14.60
Worrillow, L.J. and Allan, J.M. (2006) Deregulation of Homologous Recombination DNA Repair in Alkylating Agent-Treated Stem Cell Clones: A Possible Role in the Aetiology of Chemotherapy-Induced Leukaemia. Oncogene, 25, 1709-1720. https://doi.org/10.1038/sj.onc.1209208
Daley, J.M., Gaines, W.A., Kwon, Y. and Sung, P. (2014) Regulation of DNA Pairing in Homologous Recombination. Cold Spring Harbor Perspectives in Biology, 6, a017954. https://doi.org/10.1101/cshperspect.a017954
Jacoby, M.A., De Jesus Pizarro, R.E., Shao, J., Koboldt, D.C., Fulton, R.S., Zhou, G., et al. (2014) The DNA Double-Strand Break Response Is Abnormal in Myeloblasts from Patients with Therapy-Related Acute Myeloid Leukemia. Leukemia, 28, 1242-1251. https://doi.org/10.1038/leu.2013.368
Lai, T.H., Ewald, B., Zecevic, A., Liu, C., Sulda, M., Papaioannou, D., et al. (2016) HDAC Inhibition Induces MicroRNA-182, Which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clinical Cancer Research, 22, 3537-3549. https://doi.org/10.1158/1078-0432.CCR-15-1063
Chakraborty, S., Stark, J.M., Sun, C.L., Modi, H., Chen, W., O’Connor, T.R., et al. (2012) Chronic Myelogenous Leukemia Stem and Progenitor Cells Demonstrate Chromosomal Instability Related to Repeated Breakage-Fusion-Bridge Cycles Mediated by Increased Nonhomologous End Joining. Blood, 119, 6187-6197. https://doi.org/10.1182/blood-2011-05-352252
Ralser, M., Albrecht, M., Nonhoff, U., Lengauer, T., Lehrach, H. and Krobitsch, S. (2005) An Integrative Approach to Gain Insights into the Cellular Function of Human Ataxin-2. Journal of Molecular Biology, 346, 203-214.
Robert, C., Nagaria, PK., Pawar, N., Adewuyi, A., Gojo, I., Meyers, D.J., et al. (2016) Histone Deacetylase Inhibitors Decrease NHEJ Both by Acetylation of Repair Factors and Trapping of PARP1 at DNA Double-Strand Breaks in Chromatin. Leukemia Research, 45, 14-23.
Langelier, M.F. and Pascal, J.M. (2013) PARP-1 Mechanism for Coupling DNA Damage Detection to Poly(ADP-Ribose) Synthesis. Current Opinion in Structural Biology, 23, 134-143.
Zhao, L. and So, E.C.W. (2016) PARP-Inhibitor-Induced Synthetic Lethality for Acute Myeloid Leukemia Treatment. Experimental Hematology, 44, 902-907.
Wang, L., Cai, W., Zhang, W., Chen, X., Dong, W., Tang, D., et al. (2015) Inhibition of Poly(ADP-Ribose) Polymerase 1 Protects against Acute Myeloid Leukemia by Suppressing the Myeloproliferative Leukemia Virus Oncogene. Oncotarget, 6, 27490-27504. https://doi.org/10.18632/oncotarget.4748
Sukhanova, M., Khodyreva, S. and Lavrik, O. (2010) Poly(ADP-Ribose) Polymerase 1 Regulates Activity of DNA Polymerase Beta in Long Patch Base Excision Repair. Mutation Research, 685, 80-89.
Wang, Y.Q., Wang, P.Y., Wang, Y.T., Yang, G.F., Zhang, A. and Miao, Z.H. (2016) An Update on Poly(ADP-Ribose)Polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. Journal of Medicinal Chemistry, 59, 9575-9598. https://doi.org/10.1021/acs.jmedchem.6b00055
Muvarak, N.E., Chowdhury, K., Xia, L., Robert, C., Choi, E.Y., Cai, Y., et al. (2016) Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents—A Potential Therapy for Cancer. Cancer Cell, 30, 637-650.
Nishida, Y., Mizutani, N., Inoue, M., Omori, Y., Tamiya-Koizumi, K., Takagi, A., et al. (2014) Phosphorylated Sp1 Is the Regulator of DNA-PKcs and DNA Ligase IV Transcription of Daunorubicin-Resistant Leukemia Cell Lines. Biochimica et Biophysica Acta, 1839, 265-274.